Does Medicare Cover Pancreatic Cancer Treatment — Complete Guide 2026
Does Medicare cover pancreatic cancer treatment in 2026? Pancreatic cancer is one of the most serious cancers — the third leading cause of cancer death in the United States — with approximately 66,000 new cases diagnosed annually and the majority occurring in people over 65. Pancreatic cancer is challenging to treat because it is frequently diagnosed at an advanced stage when surgical resection is no longer possible. The good news is that yes — does Medicare cover pancreatic cancer treatment in 2026 — comprehensively across all treatment modalities including surgery, chemotherapy, targeted therapy, radiation, and palliative care. In this complete guide we explain exactly what Medicare covers for pancreatic cancer treatment in 2026. All information is sourced from Medicare.gov and CMS.gov.
Also Read —
- Does Medicare Cover Cancer Treatment 2026
- Does Medicare Cover Colon Cancer Treatment 2026
- Medicare Part B vs Part D Drug Coverage 2026
What You Will Learn — Does Medicare Cover Pancreatic Cancer
- Does Medicare cover pancreatic cancer treatment in 2026
- Does Medicare cover Whipple surgery for pancreatic cancer
- Does Medicare cover chemotherapy for pancreatic cancer
- Does Medicare cover FOLFIRINOX for pancreatic cancer
- Does Medicare cover targeted therapy for pancreatic cancer
- Does Medicare cover ERCP and biliary stenting
- Does Medicare cover radiation therapy for pancreatic cancer
- Does Medicare cover palliative and hospice care for pancreatic cancer
- How much does pancreatic cancer treatment cost with Medicare
- Frequently asked questions about Medicare pancreatic cancer coverage 2026
Does Medicare Cover Pancreatic Cancer Treatment in 2026?
Yes — does Medicare cover pancreatic cancer treatment in 2026 — comprehensively across all stages and treatment modalities. Medicare Part A covers inpatient hospitalization for Whipple surgery and other major pancreatic operations. Medicare Part B covers chemotherapy infusions, radiation therapy, ERCP and biliary stenting, and physician visits. Medicare Part D covers oral chemotherapy and targeted therapy agents. Medicare also comprehensively covers palliative care and hospice for patients with advanced pancreatic cancer.
Pancreatic cancer treatment depends on the stage — approximately 15% to 20% of patients have resectable disease at diagnosis making surgery possible. The majority present with locally advanced or metastatic disease requiring chemotherapy-based treatment. In recent years targeted therapy for patients with specific mutations — particularly BRCA mutations and KRAS G12C mutations — has provided new treatment options. Understanding does Medicare cover pancreatic cancer treatment across all these scenarios helps Medicare beneficiaries access the most appropriate care.
Does Medicare Cover Pancreatic Cancer Diagnosis?
Does Medicare cover diagnostic workup for pancreatic cancer in 2026? Yes — Medicare Part B covers all major diagnostic procedures for pancreatic cancer.
CT Scan — Covered
CT scan of abdomen and pelvis — the primary imaging study for pancreatic cancer evaluation — covered at 80% after the $257 annual Part B deductible. Dedicated pancreatic protocol CT provides detailed imaging of the pancreas and surrounding structures.
MRI and MRCP — Covered
MRI of abdomen including MRCP (magnetic resonance cholangiopancreatography) — covered at 80% after deductible for evaluating pancreatic duct anatomy and biliary system.
Endoscopic Ultrasound — Covered
EUS — endoscopic ultrasound — the most sensitive imaging test for pancreatic masses and the primary tool for obtaining tissue diagnosis — covered at 80% after deductible. EUS-guided fine needle aspiration biopsy of pancreatic masses — covered.
PET Scan — Covered
PET scan for staging and evaluating metastatic disease — covered at 80% after deductible.
CA 19-9 and CEA — Covered at $0
CA 19-9 — the primary tumor marker for pancreatic cancer — covered as diagnostic laboratory at $0. CEA — covered at $0. Ongoing CA 19-9 monitoring during treatment — covered at $0.
Molecular Testing — Covered
Comprehensive molecular profiling of pancreatic cancer — covered including:
- KRAS mutation analysis — covered
- BRCA1 and BRCA2 germline and somatic testing — covered — identifies patients who benefit from PARP inhibitors
- NTRK fusion testing — covered
- MSI/MMR testing — covered — identifies rare immunotherapy-responsive cases
- BRAF testing — covered
Does Medicare Cover Whipple Surgery for Pancreatic Cancer?
Does Medicare cover Whipple surgery (pancreaticoduodenectomy) for pancreatic cancer in 2026? Yes — Medicare covers Whipple surgery and all major pancreatic cancer surgical procedures.
Whipple Surgery — Covered
Pancreaticoduodenectomy — the Whipple procedure — is the standard surgical treatment for resectable pancreatic head cancers. It involves removal of the head of the pancreas, duodenum, gallbladder, and part of the bile duct with reconstruction. Medicare covers Whipple surgery under Part A for inpatient procedures.
Whipple surgery is one of the most complex abdominal operations performed — typically requiring 5 to 10 days of hospitalization. Medicare covers the entire hospitalization including:
- The surgical procedure
- Anesthesia
- ICU care when needed
- Surgical nursing care
- Post-surgical complications management
Distal Pancreatectomy — Covered
For body and tail pancreatic cancers — distal pancreatectomy with splenectomy — covered.
Total Pancreatectomy — Covered
Total pancreatectomy for diffuse pancreatic cancers — covered.
Minimally Invasive Pancreatic Surgery — Covered
Laparoscopic and robotic Whipple procedures — covered at standard surgical rates.
Surgery Costs with Medicare
Whipple surgery inpatient:
- Part A deductible — $1,676 per benefit period
- Days 1 to 60 — $0 after deductible
- Surgeon fee — 20% Part B coinsurance
With Medigap Plan G — Whipple surgery costs $0 after the $257 annual Part B deductible — covering both the $1,676 Part A deductible and all surgeon coinsurance. Given the complexity and extended hospitalization of Whipple surgery this Plan G benefit is particularly significant.
Does Medicare Cover Chemotherapy for Pancreatic Cancer?
Does Medicare cover chemotherapy for pancreatic cancer in 2026? Yes — Medicare covers all major pancreatic cancer chemotherapy regimens.
FOLFIRINOX — Covered Part B
FOLFIRINOX — the most effective regimen for fit patients with metastatic pancreatic cancer — is covered under Medicare Part B at 80% after the deductible. FOLFIRINOX components:
- Oxaliplatin — covered Part B
- Irinotecan — covered Part B
- Fluorouracil (5-FU) — covered Part B
- Leucovorin — covered Part B
Modified FOLFIRINOX — a less toxic version with reduced irinotecan and oxaliplatin — also covered Part B.
Gemcitabine-Based Regimens — Covered Part B
Gemcitabine — the foundational drug for pancreatic cancer chemotherapy — covered Part B:
- Gemcitabine monotherapy — covered
- Gemcitabine plus nab-paclitaxel (Abraxane) — the most widely used first-line regimen — both components covered Part B
Nab-paclitaxel (Abraxane) is a critical component of the most common pancreatic cancer chemotherapy regimen. Medicare-approved per infusion approximately $3,000 to $5,000. Your 20% coinsurance per infusion — approximately $600 to $1,000. With Medigap Plan G — $0 after annual deductible.
Adjuvant Chemotherapy After Whipple — Covered
Post-surgical chemotherapy to reduce recurrence risk:
- Modified FOLFIRINOX — standard adjuvant regimen — covered Part B
- Gemcitabine plus capecitabine — covered Part B and Part D
Gemcitabine Plus Cisplatin for BRCA-Mutant Pancreatic Cancer — Covered
For BRCA-mutant pancreatic cancer — gemcitabine plus cisplatin — covered Part B.
With Medigap Plan G — all IV chemotherapy costs $0 after the annual deductible.
Does Medicare Cover Targeted Therapy for Pancreatic Cancer?
Does Medicare cover targeted therapy for pancreatic cancer in 2026? Yes — for patients with specific molecular alterations Medicare covers targeted therapies.
PARP Inhibitors for BRCA-Mutant Pancreatic Cancer — Part D
Olaparib (Lynparza) — FDA-approved maintenance therapy for BRCA-mutant metastatic pancreatic cancer after platinum-based chemotherapy — covered Part D:
- Retail cost approximately $15,000 to $18,000 per month
- $2,000 annual Part D maximum — saves approximately $178,000 to $214,000 per year
- Critical financial protection for BRCA-mutant pancreatic cancer patients
KRAS G12C-Targeted Therapy — Covered
Adagrasib (Krazati) — for KRAS G12C-mutant pancreatic cancer — covered Part D:
- $2,000 annual Part D maximum applies
Sotorasib (Lumakras) — Covered Part D
For KRAS G12C-mutant pancreatic cancer — covered Part D — $2,000 cap.
TRK Inhibitors for NTRK Fusion — Covered Part D
Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) — for NTRK fusion-positive pancreatic cancer — covered Part D — $2,000 cap.
Pembrolizumab for MSI-H Pancreatic Cancer — Covered Part B
The approximately 1% to 2% of pancreatic cancers with MSI-H/dMMR status — immunotherapy eligible. Keytruda covered Part B at 80% after deductible — same extraordinary savings with Medigap Plan G as other Keytruda indications.
Does Medicare Cover ERCP and Biliary Stenting?
Does Medicare cover ERCP and biliary stenting for pancreatic cancer in 2026? Yes — and this is one of the most important pancreatic cancer coverage questions because biliary obstruction is one of the most common complications requiring urgent intervention.
ERCP — Covered
Endoscopic retrograde cholangiopancreatography — covered by Medicare Part B at 80% after the deductible. ERCP is performed to:
- Evaluate biliary and pancreatic duct obstruction
- Place biliary stents to relieve obstruction (jaundice)
- Obtain tissue samples for diagnosis
- Treat biliary complications after Whipple surgery
Biliary Stent Placement — Covered
Endoscopic biliary stent placement for malignant biliary obstruction — covered at 80% after deductible. Stent replacement procedures — covered as medically necessary when stents become occluded.
Percutaneous Biliary Drainage — Covered
Interventional radiology biliary drainage procedures for patients who cannot undergo ERCP — covered at 80% after deductible.
Celiac Plexus Neurolysis — Covered
EUS-guided or CT-guided celiac plexus neurolysis for pancreatic cancer pain — covered at 80% after deductible.
With Medigap Plan G — all ERCP and interventional procedures cost $0 after the annual deductible.
Does Medicare Cover Radiation Therapy for Pancreatic Cancer?
Does Medicare cover radiation therapy for pancreatic cancer in 2026? Yes — Medicare Part B covers radiation therapy for pancreatic cancer at 80% after the annual deductible.
Stereotactic Body Radiation Therapy (SBRT) — Covered
SBRT for locally advanced pancreatic cancer — 5 high-dose treatments — covered at 80% after deductible. SBRT is increasingly used for locally advanced unresectable pancreatic cancer as a less toxic alternative to conventional radiation.
Conventional External Beam Radiation — Covered
Standard fractionated radiation combined with chemotherapy for locally advanced pancreatic cancer — covered.
Intraoperative Radiation — Covered
Intraoperative radiation therapy during pancreatic surgery — covered when medically appropriate.
SBRT for Borderline Resectable Tumors — Covered
SBRT used to downstage borderline resectable pancreatic cancers before surgery — covered.
With Medigap Plan G — all radiation therapy costs $0 after the annual deductible.
Does Medicare Cover Palliative and Hospice Care for Pancreatic Cancer?
Does Medicare cover palliative and hospice care for pancreatic cancer in 2026? Yes — and given the prognosis of pancreatic cancer these benefits are particularly important.
Palliative Care — Covered
Medicare Part B covers palliative care services — focused on symptom management and quality of life — alongside active cancer treatment at 80% after the deductible. Palliative care for pancreatic cancer addresses:
- Pain management
- Nausea management
- Nutritional support
- Psychological support
- Goals of care discussions
Hospice Care — Covered at 100%
When pancreatic cancer reaches the terminal phase Medicare hospice provides:
- 24/7 support and symptom management
- Medications for comfort
- Nursing and aide services
- Social work and chaplaincy
- Respite care for caregivers
- Bereavement support
Medicare hospice is covered at 100% — no cost to the patient or family. Pancreatic cancer has a 5-year survival rate of approximately 12% — and many patients benefit from earlier hospice enrollment to maximize quality of life in their remaining time.
Pancreatic Enzyme Replacement — Covered Part D
Pancreatic exocrine insufficiency is common after Whipple surgery and in advanced pancreatic cancer:
- Pancrelipase (Creon, Zenpep, Pancreaze) — covered Part D — $2,000 annual cap applies for brand versions
- Generic pancrelipase — becoming available — more affordable
How Much Does Pancreatic Cancer Treatment Cost with Medicare in 2026?
Diagnosis
CA 19-9 monitoring — $0 as diagnostic lab CT PET imaging — approximately $100 to $300 your 20% ERCP biliary stenting — approximately $300 to $600 your 20% With Medigap Plan G — all $0 after annual deductible
Whipple Surgery
Part A deductible $1,676 plus surgeon 20% Total without supplement approximately $2,500 to $4,000 With Medigap Plan G — $0 after annual deductible
Gemcitabine plus Abraxane Chemotherapy
Per cycle — approximately $800 to $1,400 your 20% Annual without supplement approximately $10,000 to $18,000 With Medigap Plan G — $0 after annual deductible
Lynparza Maintenance BRCA-Mutant
$2,000 annual Part D maximum — saves $178,000 to $214,000
Hospice Care
$0 — 100% covered Medicare
Does Medicare Advantage Cover Pancreatic Cancer?
Does Medicare Advantage cover pancreatic cancer treatment in 2026? Yes — all Medicare Advantage plans must cover pancreatic cancer treatment.
Prior authorization — required for Whipple surgery, chemotherapy regimens, and targeted therapy. In-network surgical oncologist and comprehensive cancer center — critical for complex pancreatic surgery. Annual maximum $9,350 — most pancreatic cancer patients reach this during active treatment. Part D $2,000 maximum — same critical protection for Lynparza and KRAS-targeted therapies.
Frequently Asked Questions — Does Medicare Cover Pancreatic Cancer
Does Medicare cover pancreatic cancer treatment in 2026?
Yes — does Medicare cover pancreatic cancer comprehensively in 2026 including diagnostic EUS and CT imaging, Whipple surgery, FOLFIRINOX and gemcitabine Abraxane chemotherapy at 80%, targeted therapy including Lynparza for BRCA-mutant disease under Part D with $2,000 cap, ERCP and biliary stenting, radiation therapy, palliative care, and hospice at 100%. With Medigap Plan G most pancreatic cancer treatment costs $0 after the annual deductible.
Does Medicare cover Whipple surgery for pancreatic cancer?
Yes — Medicare covers pancreaticoduodenectomy (Whipple surgery) for resectable pancreatic cancer. The $1,676 Part A deductible applies. With Medigap Plan G the entire Whipple surgery and hospitalization costs $0 after the annual deductible — including the extended 5 to 10 day hospitalization typical of this complex procedure.
Does Medicare cover FOLFIRINOX for pancreatic cancer?
Yes — Medicare Part B covers FOLFIRINOX — oxaliplatin, irinotecan, 5-FU, and leucovorin — for metastatic pancreatic cancer at 80% after the $257 annual deductible. With Medigap Plan G all FOLFIRINOX infusions cost $0 after the annual deductible.
Does Medicare cover gemcitabine plus Abraxane for pancreatic cancer?
Yes — Medicare Part B covers both gemcitabine and nab-paclitaxel (Abraxane) for pancreatic cancer at 80% after the annual deductible. Without a supplement annual coinsurance on this regimen can reach $10,000 to $18,000. With Medigap Plan G all infusions cost $0 after the annual deductible.
Does Medicare cover Lynparza for BRCA-mutant pancreatic cancer?
Yes — Medicare Part D covers olaparib (Lynparza) maintenance therapy for BRCA-mutant metastatic pancreatic cancer. Lynparza costs approximately $15,000 to $18,000 per month at retail. The $2,000 annual Part D maximum saves patients approximately $178,000 to $214,000 annually.
Summary — Does Medicare Cover Pancreatic Cancer 2026
Does Medicare cover pancreatic cancer treatment in 2026? Yes — Medicare provides comprehensive pancreatic cancer coverage from complex Whipple surgery through chemotherapy, targeted therapy, radiation, biliary interventions, and hospice care. The financial protections are significant — Medigap Plan G eliminates coinsurance on Whipple surgery and chemotherapy while the $2,000 Part D cap protects BRCA-mutant patients taking Lynparza from $178,000 to $214,000 in annual drug costs.
For pancreatic cancer patients Medigap Plan G is particularly valuable — covering the 20% coinsurance on expensive chemotherapy regimens like gemcitabine plus Abraxane and providing complete financial protection for complex surgical procedures and the extended hospitalizations that accompany them.
For free help understanding your Medicare pancreatic cancer coverage contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org or call Medicare free at 1-800-633-4227.
This guide is for informational purposes only. Always consult your oncologist and verify current Medicare coverage at Medicare.gov.
Sources: Medicare.gov | CMS.gov | SSA.gov | AARP.org
Last updated: April 2026 | Author: James Carter, Independent Medicare Research Analyst
